Abstract
During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.
| Original language | English |
|---|---|
| Pages (from-to) | 1867-1874 |
| Number of pages | 8 |
| Journal | International journal of radiation oncology, biology, physics |
| Volume | 9 |
| Issue number | 12 |
| DOIs | |
| State | Published - Jan 1 1983 |
Fingerprint
Keywords
- Adjuvant chemotherapy of primary breast adenocarcinoma
- CAF
- CAF-Cameleon
- Chemotherapy of advanced breast adenocarcinoma
- CMF
- CMFVP
- Postoperative irradiation
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
- Radiation
Cite this
Southeastern cancer study group : Breast cancer studies 1972-1982. / Smalley, Richard V.; Bartolucci, Alfred A.; Moore, Melvin; Vogel, Charles; Carpenter, John; Perez, Carlos A.; Velez-Garcia, Enrique; Marcial, Victor; Lefante, John; Wittliff, James; Ketcham, Alfred A.; Durant, John.
In: International journal of radiation oncology, biology, physics, Vol. 9, No. 12, 01.01.1983, p. 1867-1874.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Southeastern cancer study group
T2 - Breast cancer studies 1972-1982
AU - Smalley, Richard V.
AU - Bartolucci, Alfred A.
AU - Moore, Melvin
AU - Vogel, Charles
AU - Carpenter, John
AU - Perez, Carlos A.
AU - Velez-Garcia, Enrique
AU - Marcial, Victor
AU - Lefante, John
AU - Wittliff, James
AU - Ketcham, Alfred A.
AU - Durant, John
PY - 1983/1/1
Y1 - 1983/1/1
N2 - During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.
AB - During the past 10 years, the Southeastern Cancer Study Group (SECSG) has been engaged in one major adjuvant study and three major advanced disease studies for patients with adenocarcinoma of the breast. The adjuvant study is demonstrating that six months of adjuvant CMF is the therapeutic equivalent of 12 months and that post-operative irradiation is of no added therapeutic benefit. In patients with advanced disease, a low dose 5 drug combination of CMFVP induces more objective responses than single agent 5FU, but improves survival only for those patients with liver metastases when compared to the sequential use of the same 5 single agents. The three drug combination, CAF, utilizing doxorubicin, induces more objective responses than low dose CMFVP, but it does not improve overall survival. The subsets of patients with bone-only metastases, with local chest wall recurrence and with nodular lung metastases benefit from CAF in terms of a longer duration of disease control and longer duration of unmaintained remission, but have only a marginal improvement in survival. The addition of a phase active combination, CAMELEON, (i.e., sequentially alternating therapy) to CAF has not improved the duration of disease control and survival for patients with liver metastases, lymphangitic and nodular lung metastases compared to CAF. Aggressive combination chemotherapeutic approaches to patients with advanced disease provide better and longer disease and tumor control but only marginal improvements in overall survival. Adding additional agents to a maximally tolerable regimen has not improved the therapeutic outcome.
KW - Adjuvant chemotherapy of primary breast adenocarcinoma
KW - CAF
KW - CAF-Cameleon
KW - Chemotherapy of advanced breast adenocarcinoma
KW - CMF
KW - CMFVP
KW - Postoperative irradiation
UR - http://www.scopus.com/inward/record.url?scp=0021040215&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021040215&partnerID=8YFLogxK
U2 - 10.1016/0360-3016(83)90354-1
DO - 10.1016/0360-3016(83)90354-1
M3 - Article
C2 - 6607245
AN - SCOPUS:0021040215
VL - 9
SP - 1867
EP - 1874
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
SN - 0360-3016
IS - 12
ER -